Related Experiment Video

Updated: Aug 20, 2026

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

A new human breast carcinoma cell line resistant to DNA-damaging drugs

Vera V Levina1, Eugeny A Drobchenko, Elena V Shabalina

  • 1Petersburg Nuclear Physics Institute, Russian Academy of Science, Gatchina, Russian Federation. veralevina@mail.ru

Alternatives to Laboratory Animals : ATLA
|January 18, 2005
PubMed

Insights

Researchers developed a new breast cancer cell line (MCF7HoeR-7) that actively removes Hoechst 33342 dye from DNA. This DNA clearing mechanism confers resistance to chemotherapy drugs, suggesting a novel pathway for multidrug resistance in tumors.

Area of Science:

  • Cancer Biology
  • Molecular Pharmacology
  • Cellular Mechanisms

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • The vital dye Hoechst 33342 (Ho342) is used to study DNA interactions in cells.
  • Active dissociation of Ho342 from DNA, termed 'DNA clearing,' is a poorly understood phenomenon.

Purpose of the Study:

  • To investigate the mechanism of active DNA clearing of Hoechst 33342 (Ho342).
  • To characterize a novel human breast carcinoma cell line with enhanced DNA clearing ability.
  • To determine if DNA clearing represents an atypical multidrug resistance (MDR) mechanism.

Main Methods:

  • Isolation of a new cell line (MCF7HoeR-7) from parent MCF7 cells via step-wise selection with Ho342.
  • Detailed characterization of MCF7HoeR-7 cells, comparing them to parental MCF7 and a known MDR cell line (MCF7/Adr).
  • Assessment of cellular properties including growth rate, DNA content, chromosome number, drug resistance, and transport protein expression.

Main Results:

  • MCF7HoeR-7 cells exhibit significantly enhanced DNA clearing ability.
  • These cells show increased population growth rate, lower DNA content, and reduced chromosome number.
  • MCF7HoeR-7 cells display high resistance to Ho342 and cross-resistance to etoposide, a topoisomerase II inhibitor.
  • Similar expression levels of transport proteins were observed between MCF7HoeR-7 and parental MCF7 cells.

Conclusions:

  • DNA clearing is an atypical multidrug resistance (MDR) mechanism in tumor cells.
  • The novel MCF7HoeR-7 cell line provides a valuable model for studying DNA clearing and MDR.
  • This finding has implications for understanding and overcoming chemotherapy resistance in breast cancer.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
What is Cancer?02:12

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cell Lines01:16

Cell Lines

A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...